<P>When a biological drug patent expires, alternative biosimilar products are developed. The development of biosimilar products is complicated and involves numerous considerations and steps. The assessment of biosimilarity and interchangeability is also complicated and difficult. <B><EM>Biosimilar D
BIOSIMILAR DRUG PRODUCT DEVELOPMENT
โ Scribed by Laszlo Endrenyi, Dr. Paul Declerck, Shein-Chung Chow
- Publisher
- CRC Press
- Year
- 2017
- Tongue
- English
- Leaves
- 496
- Series
- Drugs and the Pharmaceutical Sciences
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
When a biological drug patent expires, alternative biosimilar products are developed. The development of biosimilar products is complicated and involves numerous considerations and steps. The assessment of biosimilarity and interchangeability is also complicated and difficult. Biosimilar Drug Product Development presents current issues for the development of biosimilars and gives detailed reviews of its various stages and contributing factors as well as relevant regulatory pathways and pre- and post-approval issues.
โฆ Table of Contents
Content: Analytical characterization. Immunogenicity. Animal studies. Clinical development. Manufacturing, process control. Extrapolation of indications. Interchangeability, substitution. Pharmacovigilance. Statistical issues. Regulatory issues.
๐ SIMILAR VOLUMES
<p><span>Methodologies for Biosimilar Product Development</span><span> covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the m
<p>The purpose of this book is to give a concise introduction to development and analysis of pharmaceutical biologics for those in the pharmaceutical industry who are switching focus from small molecules to biologics processing, analysis, and delivery. In order to maintain a limited focus, Introduct
<p><p>This book provides a comprehensive overview of the biosimilar regulatory framework, the development process and clinical aspects for development of biosimilars. The development path of a biosimilar is just as unique as a development path of a new drug, tailored by the mechanism of action, the